Course Progress 70%
The Menopause Blueprint™ Exam Prep

Statistics You Need to Know

Master these high-yield statistics, demographics, and clinical probabilities to strengthen your certification exam preparation and reinforce the numbers that matter most in menopause care.

40%
Many U.S. women may spend up to 40% of life in postmenopause.
1 in 3
Women have a lifetime risk of about 1 in 3 for developing cancer.
75%
Hormone therapy can reduce vasomotor symptom frequency by about 75%.
40–50%
Lifetime osteoporotic fracture risk for postmenopausal women.

Demographics & Life Expectancy

  • Natural menopause: usually occurs between ages 40–58.
  • Early menopause: final menstrual period before age 45.
  • Primary ovarian insufficiency: before age 40.
  • Life expectancy: U.S. females average 81.2 years; probability of survival from age 50 to 80 is 67.2%.

Ovarian Reserve & Hormonal Changes

  • Only about 400–500 oocytes are ovulated in a lifetime.
  • AMH peaks around age 24.5 and declines with age; hormonal contraceptives may lower AMH by ~30–50%.
  • FSH ≥ 25 IU/L is recognized as a marker of late transition in STRAW+10.
  • SHBG declines by ~40% during transition, with free androgen index increasing by ~80%.

Health Risks & Morbidity

  • CVD: the number one cause of death in women, responsible for 1 in every 3 deaths.
  • Stroke risk: at age 55, lifetime risk is 1 in 5 for women.
  • Metabolic syndrome: prevalence in midlife women is 22–39% and doubles CVD risk.
  • Depression: women are at 2–4× greater risk of a first depressive episode during the menopause transition.
  • Bone health: 15.4% of U.S. women ≥50 have osteoporosis; 51.4% have low bone mass.
  • GSM/VVA: prevalence ranges from 20% to 84%, and symptoms worsen over time unlike vasomotor symptoms.